Adicet Bio, Inc. Announces Closing of $152 Million Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 02/16/21
Adicet Bio, Inc. Announces Pricing of $135 Million Public Offering of Common Stock and Concurrent Private PlacementGlobeNewsWire • 02/10/21
Adicet Bio, Inc. Announces Proposed Public Offering of Common Stock and Concurrent Private PlacementGlobeNewsWire • 02/09/21
Adicet: Promising 2021 Therapeutic Initiations, Cash Of $108 Million, And New ManagementSeeking Alpha • 12/28/20
Adicet Bio to Participate in Fireside Chat at JMP Securities Hematology SummitGlobeNewsWire • 12/08/20
Adicet Reports Third Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 11/05/20
Adicet Announces FDA Clearance of IND Application for First-in-Class Allogeneic CAR Gamma-Delta T Cell TherapyGlobeNewsWire • 10/22/20
Adicet Bio, Inc. Determines Not to Proceed with Public Offering of Common StockGlobeNewsWire • 09/23/20